Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 19

1.

Trabectedin triggers direct and NK-mediated cytotoxicity in multiple myeloma.

Cucè M, Gallo Cantafio ME, Siciliano MA, Riillo C, Caracciolo D, Scionti F, Staropoli N, Zuccalà V, Maltese L, Di Vito A, Grillone K, Barbieri V, Arbitrio M, Di Martino MT, Rossi M, Amodio N, Tagliaferri P, Tassone P, Botta C.

J Hematol Oncol. 2019 Mar 21;12(1):32. doi: 10.1186/s13045-019-0714-9.

2.

Diagnosis and first-line treatment of non-small cell lung cancer in the era of novel immunotherapy: recommendations for clinical practice.

De Marinis F, Barberis M, Barbieri V, Marchianò A, Gasparini S, Migliorino MR, Romano G, Spinnato F, Vitiello F, Gridelli C.

Expert Rev Respir Med. 2019 Mar;13(3):217-228. doi: 10.1080/17476348.2019.1569517. Epub 2019 Jan 24.

PMID:
30640563
3.

Pharmacogenomic Profiling of ADME Gene Variants: Current Challenges and Validation Perspectives.

Arbitrio M, Martino MTD, Scionti F, Barbieri V, Pensabene L, Tagliaferri P.

High Throughput. 2018 Dec 18;7(4). pii: E40. doi: 10.3390/ht7040040. Review.

4.

From Single Level Analysis to Multi-Omics Integrative Approaches: A Powerful Strategy towards the Precision Oncology.

Gallo Cantafio ME, Grillone K, Caracciolo D, Scionti F, Arbitrio M, Barbieri V, Pensabene L, Guzzi PH, Di Martino MT.

High Throughput. 2018 Oct 26;7(4). pii: E33. doi: 10.3390/ht7040033. Review.

5.

The Era of PARP inhibitors in ovarian cancer: "Class Action" or not? A systematic review and meta-analysis.

Staropoli N, Ciliberto D, Del Giudice T, Iuliano E, Cucè M, Grillone F, Salvino A, Barbieri V, Russo A, Tassone P, Tagliaferri P.

Crit Rev Oncol Hematol. 2018 Nov;131:83-89. doi: 10.1016/j.critrevonc.2018.08.011. Epub 2018 Sep 3. Review.

PMID:
30293710
6.

BMP9 counteracts the tumorigenic and pro-angiogenic potential of glioblastoma.

Porcù E, Maule F, Boso D, Rampazzo E, Barbieri V, Zuccolotto G, Rosato A, Frasson C, Viola G, Della Puppa A, Basso G, Persano L.

Cell Death Differ. 2018 Nov;25(10):1808-1822. doi: 10.1038/s41418-018-0149-9. Epub 2018 Jul 5.

PMID:
29977042
7.

A BARF1-specific mAb as a new immunotherapeutic tool for the management of EBV-related tumors.

Turrini R, Merlo A, Martorelli D, Faè DA, Sommaggio R, Montagner IM, Barbieri V, Marin O, Zanovello P, Dolcetti R, Rosato A.

Oncoimmunology. 2017 Mar 16;6(4):e1304338. doi: 10.1080/2162402X.2017.1304338. eCollection 2017.

8.

Analysis of DNA-damage response to ionizing radiation in serum-shock synchronized human fibroblasts.

Corrà S, Salvadori R, Bee L, Barbieri V, Mognato M.

Cell Biol Toxicol. 2017 Aug;33(4):373-388. doi: 10.1007/s10565-017-9394-9. Epub 2017 May 3.

9.

Identification of polymorphic variants associated with erlotinib-related skin toxicity in advanced non-small cell lung cancer patients by DMET microarray analysis.

Arbitrio M, Di Martino MT, Barbieri V, Agapito G, Guzzi PH, Botta C, Iuliano E, Scionti F, Altomare E, Codispoti S, Conforti S, Cannataro M, Tassone P, Tagliaferri P.

Cancer Chemother Pharmacol. 2016 Jan;77(1):205-9. doi: 10.1007/s00280-015-2916-3. Epub 2015 Nov 25.

PMID:
26607259
10.

Retaining the long-survive capacity of Circulating Tumor Cells (CTCs) followed by xeno-transplantation: not only from metastatic cancer of the breast but also of prostate cancer patients.

Rossi E, Rugge M, Facchinetti A, Pizzi M, Nardo G, Barbieri V, Manicone M, De Faveri S, Chiara Scaini M, Basso U, Amadori A, Zamarchi R.

Oncoscience. 2013 Dec 31;1(1):49-56. eCollection 2014.

11.

Functional avidity-driven activation-induced cell death shapes CTL immunodominance.

Dalla Santa S, Merlo A, Bobisse S, Ronconi E, Boldrin D, Milan G, Barbieri V, Marin O, Facchinetti A, Biasi G, Dolcetti R, Zanovello P, Rosato A.

J Immunol. 2014 Nov 1;193(9):4704-11. doi: 10.4049/jimmunol.1303203. Epub 2014 Sep 22.

12.

The DNA-damage response to γ-radiation is affected by miR-27a in A549 cells.

Di Francesco A, De Pittà C, Moret F, Barbieri V, Celotti L, Mognato M.

Int J Mol Sci. 2013 Sep 2;14(9):17881-96. doi: 10.3390/ijms140917881.

13.

Toll-like receptor 2 regulates intestinal inflammation by controlling integrity of the enteric nervous system.

Brun P, Giron MC, Qesari M, Porzionato A, Caputi V, Zoppellaro C, Banzato S, Grillo AR, Spagnol L, De Caro R, Pizzuti D, Barbieri V, Rosato A, Sturniolo GC, Martines D, Zaninotto G, Palù G, Castagliuolo I.

Gastroenterology. 2013 Dec;145(6):1323-33. doi: 10.1053/j.gastro.2013.08.047. Epub 2013 Aug 28.

PMID:
23994200
14.

Systemic inflammatory status at baseline predicts bevacizumab benefit in advanced non-small cell lung cancer patients.

Botta C, Barbieri V, Ciliberto D, Rossi A, Rocco D, Addeo R, Staropoli N, Pastina P, Marvaso G, Martellucci I, Guglielmo A, Pirtoli L, Sperlongano P, Gridelli C, Caraglia M, Tassone P, Tagliaferri P, Correale P.

Cancer Biol Ther. 2013 Jun;14(6):469-75. doi: 10.4161/cbt.24425.

15.

Role of systemic chemotherapy in the management of resected or resectable colorectal liver metastases: a systematic review and meta-analysis of randomized controlled trials.

Ciliberto D, Prati U, Roveda L, Barbieri V, Staropoli N, Abbruzzese A, Caraglia M, Di Maio M, Flotta D, Tassone P, Tagliaferri P.

Oncol Rep. 2012 Jun;27(6):1849-56. doi: 10.3892/or.2012.1740. Epub 2012 Mar 22. Review.

PMID:
22446591
16.

Capecitabine-induced, rapid decrease of renal function due to drug dispensing error in a hospital pharmacy.

Di Mizio G, Gallelli L, Barbieri V, Loiacono D, Colosimo F, Rende P, Di Nunzio C, Ricci P.

J Clin Pharmacol. 2011 Jan;51(1):117-9. doi: 10.1177/0091270010365552. Epub 2010 Mar 22. No abstract available.

PMID:
20308690
17.

Interferon-alpha counteracts the angiogenic switch and reduces tumor cell proliferation in a spontaneous model of prostatic cancer.

Persano L, Moserle L, Esposito G, Bronte V, Barbieri V, Iafrate M, Gardiman MP, Larghero P, Pfeffer U, Naschberger E, Stürzl M, Indraccolo S, Amadori A.

Carcinogenesis. 2009 May;30(5):851-60. doi: 10.1093/carcin/bgp052. Epub 2009 Feb 23.

PMID:
19237608
18.

The IASLC Lung Cancer Staging Project: revision proposal of pleural effusion and controlateral nodule staging.

Barbieri V, Tassone P, Tagliaferri P.

J Thorac Oncol. 2008 Mar;3(3):317; author reply 317-8. doi: 10.1097/JTO.0b013e318166b84a. No abstract available.

19.

IL-2 signals through Sgk1 and inhibits proliferation and apoptosis in kidney cancer cells.

Amato R, Menniti M, Agosti V, Boito R, Costa N, Bond HM, Barbieri V, Tagliaferri P, Venuta S, Perrotti N.

J Mol Med (Berl). 2007 Jul;85(7):707-21. Epub 2007 Jun 15.

PMID:
17571248

Supplemental Content

Loading ...
Support Center